<DOC>
	<DOC>NCT01535677</DOC>
	<brief_summary>This is an open-label, randomised study to compare the similarity of a combination Dapagliflozin/Metformin tablet with the two drugs administered separately under fasting and fed conditions in healthy volunteers.</brief_summary>
	<brief_title>To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately</brief_title>
	<detailed_description>A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5.0 mg/850 mg) Relative to a 5.0 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy volunteers aged 18 to 55 years inclusive with suitable veins for cannulation or repeated vein puncture Male subjects should be willing to use barrier contraception ie, condoms and spermicide, from the day of dosing until at least 3 months after dosing with the investigational product Nonpregnant, nonlactating female subjects who if premenopausal are using adequate birth control eg, oral, injectable, transdermal or implanted hormonal contraceptives, vaginal contraceptive ring, intrauterine device (IUD)/intrauterine systems Have a body mass index (BMI) between 18.5 and 30.0 kg/m2 inclusive (ie, within 15% of normal range) and weigh at least 50 kg and no more than 100 kg. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with individual safety evaluation Current smokers who smoke more than 5 cigarettes per day (or equivalent use of tobacco products) or cannot give up smoking during the study Excessive intake of caffeine containing drinks eg, coffee, tea, caffeine containing energy drinks and cola (more than 5 cups of coffee or equivalent per day) Plasma donation within one month of screening or any blood donation/blood loss &gt;500 mL during the 3 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy volunteers</keyword>
	<keyword>cross-over study</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Cmax</keyword>
	<keyword>tmax</keyword>
	<keyword>AUC</keyword>
	<keyword>AUC(0-t)</keyword>
	<keyword>λz</keyword>
	<keyword>tlast</keyword>
</DOC>